Atacand (Candesartan) Real Life Study
Information source: AstraZeneca
Information obtained from ClinicalTrials.gov on August 08, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypertension
Intervention: Candesartan Cilexetil (Drug); Losartan (Drug)
Phase: N/A
Status: Recruiting
Sponsored by: AstraZeneca Official(s) and/or principal investigator(s):
Jan Stålhammar, MD, Principal Investigator, Affiliation: Eriksbergs vårdcentral
Overall contact:
AstraZeneca Norway Study Information, Phone: + 47 21 00 64 00, Email: paal.hasvold@astrazeneca.com
Summary
This study is a Swedish historical cohort study in patients prescribed Atacand or Cozaar for
hypertension by selected primary care centres. Data will be extracted anonymously from
electronic medical records. In addition, data regarding morbidity and mortality will be
collected by merging the cohort with the following national registries: the Hospital
Discharge Register (Slutenvårdsregistret), the Cause of Death Register and the Heart
Intensive Care Admission (RIKS-HIA)
Clinical Details
Official title: A REtrospective Study on the Effects of cAndesartan vs. Losartan on Blood Pressure, Health Care Consumption and cardiovascuLar Events In a "Real-liFe" GP sEtting in Sweden
Study design: Cohort, Retrospective
Primary outcome: Blood pressure recordings will be followed for the available observation periods with detail to when and to what degree levels less than 140/90 are reached.
Secondary outcome: Cardiovascular disease states and procedures in the background and over the entire observation period will be identified by use of ICD-9 and ICD-10 coding for diseases of the cardiovascular system. Specifically are death, acute cardiovascular events, newHealth care consumption will be assessed as contacts with health care providers, in-hospital time periods for cardiovascular disease states with associated therapeutic procedures, and times spent within various levels of care (e.g. ICU and general ward).
Eligibility
Minimum age: 17 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Recorded blood pressure prior to therapy of > 140 and/or 90 mmHg
- Diagnosed as hypertensive within 15 months
Exclusion Criteria:
- Previous prescription within 15 months any drug from the ATC groups C02, C03, C07 -
C09 inclusive
Locations and Contacts
AstraZeneca Norway Study Information, Phone: + 47 21 00 64 00, Email: paal.hasvold@astrazeneca.com
Research Site, Uppsala, Sweden; Recruiting
Additional Information
Starting date: February 2008
Ending date: April 2008
Last updated: February 8, 2008
|
